These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9194208)

  • 21. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
    Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
    Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lung injury associated with bucillamine therapy].
    Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T
    Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis].
    Kishimoto N; Fujii K
    Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):321-5. PubMed ID: 12096503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study.
    Suda A; Nagaoka S; Ohono S; Ideguchi H; Soga T; Ishigatsubo Y
    Mod Rheumatol; 2008; 18(6):609-14. PubMed ID: 18682889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
    Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank.
    Frank M
    Future Microbiol; 2022 Feb; 17(3):157-159. PubMed ID: 35044238
    [No Abstract]   [Full Text] [Related]  

  • 27. [A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine].
    Matsushima H; Takayanagi N; Sakamoto T; Motegi M; Ubukata M; Yanagisawa T; Sugita Y; Kanazawa M; Kawabata Y
    Nihon Kokyuki Gakkai Zasshi; 2001 Jan; 39(1):55-9. PubMed ID: 11296388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Auranofin or D-penicillamine in the treatment of rheumatoid arthritis.
    Hochberg MC
    Ann Intern Med; 1986 Oct; 105(4):528-35. PubMed ID: 3092712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the effects of the antirheumatic drugs, bucillamine and D-penicillamine, on mitogen-induced proliferation of mouse spleen cells.
    Mita S; Matsunaga K
    Agents Actions; 1990 Jun; 30(3-4):363-8. PubMed ID: 2386109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
    Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.
    Jessop JD; O'Sullivan MM; Lewis PA; Williams LA; Camilleri JP; Plant MJ; Coles EC
    Br J Rheumatol; 1998 Sep; 37(9):992-1002. PubMed ID: 9783766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug induced nephrotic syndrome].
    Ohno I
    Nihon Rinsho; 2004 Oct; 62(10):1919-24. PubMed ID: 15500140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine.
    Nanke Y; Iwatani M; Kobashigawa T; Yago T; Yamanaka H; Kotake S
    Mod Rheumatol; 2009; 19(6):681-6. PubMed ID: 19711150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats.
    Hayashi M; Matsunaga K; Okahara A; Mita S
    J Rheumatol; 1991 May; 18(5):691-5. PubMed ID: 1865415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yellow nails under bucillamine therapy for rheumatoid arthritis: a report of two cases.
    Yamamoto T; Yokozeki H
    Rheumatol Int; 2007 Apr; 27(6):603-4. PubMed ID: 17103174
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis.
    Sekiguchi N; Kameda H; Amano K; Takeuchi T
    Mod Rheumatol; 2006; 16(2):85-91. PubMed ID: 16633927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature.
    Isozaki T; Kimura M; Ikegaya N; Arai T; Fujigaki Y; Hishida A; Kaneko E
    Clin Investig; 1992 Nov; 70(11):1036-42. PubMed ID: 1472834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiographic appearance of bronchiolitis obliterans organizing pneumonia (BOOP) developing during Bucillamine treatment for rheumatoid arthritis.
    Kajiya T; Kuroda A; Hokonohara D; Tei C
    Am J Med Sci; 2006 Jul; 332(1):39-42. PubMed ID: 16845241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of bucillamine-induced interstitial pneumonia with positive lymphocyte stimulation test for bucillamine using bronchoalveolar lavage lymphocytes.
    Saito Y; Nei T; Abe S; Usuki J; Azuma A; Nakayama T; Fukuda Y; Kudoh S
    Intern Med; 2007; 46(20):1739-43. PubMed ID: 17938531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced pemphigus: A systematic review of 170 patients.
    Ghaedi F; Etesami I; Aryanian Z; Kalantari Y; Goodarzi A; Teymourpour A; Tavakolpour S; Mahmoudi H; Daneshpazhooh M
    Int Immunopharmacol; 2021 Mar; 92():107299. PubMed ID: 33418246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.